Unlikely to cause harm — often a labeling or packaging issue.
Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability
| Brand name | DABIGATRAN ETEXILATE |
| Generic name | DABIGATRAN ETEXILATE |
| Active ingredient(s) | DABIGATRAN ETEXILATE MESYLATE |
| Distributed by / for | MAJOR PHARMACEUTICALS, Indianapolis, IN 46268 |
| NDC | 0904-7255-68 |
| Full product label | Dabigatran Etexilate Capsules, 150 mg, 60-count (6x10) blister pack further packaged in a carton, Rx only, Manufactured by: Alkem Laboratories Ltd., Mumbai, INDIA, Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, IN 46268, NDC 0904-7255-68. |
| Recalling firm | Ascend Laboratories, LLC |
| Distribution | USA Nationwide |
| Quantity | 3,600 cartons x 6 x 10 (in blister pack) |
| Recall initiated | 2026-07-16 |
| Report date | 2026-08-05 |
| Recall completed | — |
| Recall number | D-0737-2026 |
| Classification | Class III |
| FDA status | Ongoing |
| Origin on file | Bedminster NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗